DURECT (DRRX) Competitors $0.95 +0.09 (+10.72%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends DRRX vs. JMAC, ADVM, INMB, CRDL, DERM, IMUX, ANRO, IPSC, SKYE, and MNOVShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Maxpro Capital Acquisition (JMAC), Adverum Biotechnologies (ADVM), INmune Bio (INMB), Cardiol Therapeutics (CRDL), Journey Medical (DERM), Immunic (IMUX), Alto Neuroscience (ANRO), Century Therapeutics (IPSC), Skye Bioscience (SKYE), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry. DURECT vs. Maxpro Capital Acquisition Adverum Biotechnologies INmune Bio Cardiol Therapeutics Journey Medical Immunic Alto Neuroscience Century Therapeutics Skye Bioscience MediciNova DURECT (NASDAQ:DRRX) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends. Do analysts rate DRRX or JMAC? DURECT presently has a consensus target price of $5.00, suggesting a potential upside of 426.32%. Given DURECT's stronger consensus rating and higher probable upside, equities research analysts plainly believe DURECT is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DURECT 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, DRRX or JMAC? Maxpro Capital Acquisition has lower revenue, but higher earnings than DURECT. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDURECT$8.59M3.43-$27.62M-$0.61-1.56Maxpro Capital AcquisitionN/AN/AN/AN/AN/A Which has more volatility & risk, DRRX or JMAC? DURECT has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Does the media refer more to DRRX or JMAC? In the previous week, DURECT had 2 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 2 mentions for DURECT and 0 mentions for Maxpro Capital Acquisition. DURECT's average media sentiment score of 0.00 equaled Maxpro Capital Acquisition'saverage media sentiment score. Company Overall Sentiment DURECT Neutral Maxpro Capital Acquisition Neutral Do institutionals and insiders believe in DRRX or JMAC? 28.0% of DURECT shares are held by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 3.2% of DURECT shares are held by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in DRRX or JMAC? DURECT received 316 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformDURECTOutperform Votes31663.33% Underperform Votes18336.67% Maxpro Capital AcquisitionN/AN/A Is DRRX or JMAC more profitable? Maxpro Capital Acquisition has a net margin of 0.00% compared to DURECT's net margin of -198.58%. Maxpro Capital Acquisition's return on equity of 0.00% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets DURECT-198.58% -300.62% -65.17% Maxpro Capital Acquisition N/A N/A N/A SummaryDURECT beats Maxpro Capital Acquisition on 7 of the 12 factors compared between the two stocks. Ad ProsperityPubWhat most folks don’t know about oil (BIG missed opportunity)$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.And expects this underappreciated niche to continue rallying well into 2026. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.49M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-1.5610.5991.3417.19Price / Sales3.43195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book1.905.104.794.78Net Income-$27.62M$151.51M$120.07M$225.60M7 Day Performance26.67%-2.14%-1.90%-1.24%1 Month Performance11.67%-3.13%11.43%3.06%1 Year Performance83.47%11.51%30.59%16.50% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT2.6376 of 5 stars$0.95+10.7%$5.00+426.3%+89.2%$29.49M$8.59M-1.5680Analyst ForecastNews CoverageJMACMaxpro Capital AcquisitionN/A$8.34+7.8%N/A+837.6%$112.00MN/A0.002,021Gap DownADVMAdverum Biotechnologies4.215 of 5 stars$5.38+0.2%$27.83+417.3%-40.0%$111.92M$1M-0.90190Analyst DowngradeNews CoverageINMBINmune Bio1.4934 of 5 stars$5.01+5.5%$20.00+299.2%-55.7%$111.08M$42,000.00-2.1810CRDLCardiol Therapeutics2.2494 of 5 stars$1.33-0.4%$8.75+560.4%+44.0%$108.26M$60,000.00-3.4120Analyst ForecastAnalyst RevisionNews CoverageGap DownDERMJourney Medical2.5489 of 5 stars$5.00-1.8%$9.38+87.5%N/A$104.45M$79.18M-5.4190IMUXImmunic2.9378 of 5 stars$1.16+2.2%$11.80+921.6%-20.6%$104.04MN/A-0.9270Positive NewsANROAlto Neuroscience3.2602 of 5 stars$3.84+0.3%$20.00+420.8%N/A$103.57M$210,000.000.00N/AIPSCCentury Therapeutics1.8179 of 5 stars$1.21-0.8%$11.60+858.7%-52.6%$102.89M$2.68M-0.66170High Trading VolumeSKYESkye Bioscience1.9975 of 5 stars$3.38+0.9%$18.67+452.3%-10.6%$102.54MN/A0.0011News CoveragePositive NewsGap DownMNOVMediciNova2.1557 of 5 stars$2.09-0.5%$9.00+330.6%+43.7%$102.51M$1M-9.9510Analyst Forecast Related Companies and Tools Related Companies JMAC Competitors ADVM Competitors INMB Competitors CRDL Competitors DERM Competitors IMUX Competitors ANRO Competitors IPSC Competitors SKYE Competitors MNOV Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DRRX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRRX Stock Alerts